Newsletter | April 30, 2019

04.30.19 -- Are Today's Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?

 
Industry Insights
Are Today’s Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?
Article | By Dr. Mats Lundgren, GE Healthcare Life Sciences

By recognizing the limitations of today’s production processes, the industry may be able to overcome the challenges, complexity, and high cost of manufacturing vaccines and viral vector-based therapies.

The Right Biomanufacturing Partner Can Improve Flexibility And Mitigate Risks From Forecasting
Article | Thermo Fisher Scientific

While forecasts can never be 100 percent accurate, the goal for biopharmaceutical forecasters should be to minimize the degree of inaccuracies as much as possible.

Most Popular News
Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.